Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338776 | 0.94 | FGFR1 (0.55) | FGFR1HSD17B10GAAL3MBTL1ALDH1A1 | |
| SCHEMBL22449395 | 0.87 | ALDH1A1 (0.53) | FGFR1HSD17B10GAAL3MBTL1ALDH1A1 | |
| SCHEMBL22449397 | 0.84 | ALDH1A1 (0.56) | FGFR1HSD17B10GAAL3MBTL1ALDH1A1 | |
| SCHEMBL12075903 | 0.84 | FGFR1 (0.48) | FGFR1HSD17B10GAAL3MBTL1ALDH1A1 | |
| SCHEMBL12075901 | 0.84 | FGFR1 (0.48) | FGFR1HSD17B10GAAL3MBTL1ALDH1A1 | |
| SCHEMBL26758104 | 0.83 | L3MBTL1 (0.60) | HSD17B10GAAL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL17342218 | 0.81 | FGFR1 (0.47) | FGFR1GAAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL18762218 | 0.81 | FGFR1 (0.47) | FGFR1GAAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1871066 | 0.78 | HCAR1 (0.54) | FGFR1GAAALDH1A1NPC1MAPT | |
| SCHEMBL1594855 | 0.77 | ALDH1A1 (0.49) | HSD17B10GAAL3MBTL1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1521/4885HSD17B10 1553/4885GAA 4379/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1596/4885HSD17B10 1553/4885GAA 4317/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | FGFR1 1437/4885HSD17B10 1556/4885GAA 4272/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1521/4885HSD17B10 1553/4885GAA 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.